GLP-1 and Testosterone: Does Weight Loss Restore Testosterone in Obese Men?
Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
Obesity is a significant contributor to hypogonadism in men, characterized by reduced testosterone levels.
# GLP-1 and Testosterone: Does Weight Loss Restore Testosterone in Obese Men?
Obesity is a significant contributor to hypogonadism in men, characterized by reduced testosterone levels. This often leads to a cascade of adverse health effects, including decreased libido, erectile dysfunction, reduced muscle mass, increased fat mass, and impaired quality of life. Glucagon-like peptide-1 (GLP-1) receptor agonists, primarily known for their efficacy in weight management and glycemic control, are increasingly recognized for their potential to positively impact testosterone levels in obese men. The primary mechanism appears to be through the substantial weight loss they induce.
The Link Between Obesity and Low Testosterone
Adipose tissue, particularly visceral fat, is metabolically active and contains aromatase, an enzyme that converts testosterone into estrogen. In obese men, increased aromatase activity leads to higher estrogen levels, which in turn suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing luteinizing hormone (LH) production and subsequently testicular testosterone synthesis. Additionally, obesity is associated with increased systemic inflammation and insulin resistance, both of which can directly impair Leydig cell function and testosterone production.
GLP-1 Agonists and Testosterone Restoration Through Weight Loss
GLP-1 receptor agonists, such as semaglutide and liraglutide, facilitate significant and sustained weight loss by reducing appetite, increasing satiety, and improving metabolic parameters. This weight reduction directly addresses the root causes of obesity-related hypogonadism:
Reduced Aromatase Activity: As fat mass decreases, particularly visceral fat, aromatase activity is reduced, leading to lower estrogen levels. This disinhibits the HPG axis, allowing for increased LH secretion and endogenous testosterone production.
Improved Insulin Sensitivity and Reduced Inflammation: Weight loss improves insulin sensitivity and reduces chronic low-grade inflammation, both of which can directly enhance Leydig cell function and testosterone synthesis.
Clinical studies have consistently shown that GLP-1 anti-obesity medications can enhance testosterone levels in men with obesity [1, 2]. Research indicates that testosterone improvements tend to correlate with the degree of fat loss rather than the specific medication used, suggesting that weight reduction is the primary driver of this hormonal restoration [3]. For instance, a 10% reduction in body weight via GLP-1 therapy has been found to significantly increase testosterone levels [4].
Clinical Evidence and Outcomes
Several studies highlight the positive impact of GLP-1 agonists on testosterone:
Men using dulaglutide, semaglutide, or tirzepatide have shown a rise in free testosterone after initiating treatment, with some achieving normal total testosterone levels [5].
One study demonstrated that semaglutide therapy for 24 weeks in men with obesity and insulin resistance resulted in a 12% decrease in body weight and a 20% increase in total testosterone levels [6].
While the effect on testosterone levels is often described as
modest, it is often clinically significant, especially when combined with the overall metabolic improvements.
Semaglutide vs. TRT for Testosterone Improvement
It's important to differentiate the role of GLP-1 agonists from Testosterone Replacement Therapy (TRT). While TRT directly provides exogenous testosterone, GLP-1 agonists work by restoring endogenous production through weight loss and metabolic improvement. A study comparing semaglutide to TRT found that semaglutide was superior in improving body composition and comparably increased testosterone along with improved AMS (Aging Male Symptoms) scores [8]. This suggests that for obese men with hypogonadism, addressing the underlying obesity with GLP-1 agonists can be a more holistic approach, leading to broader health benefits beyond just testosterone normalization.
Clinical Implications
For clinicians, GLP-1 receptor agonists offer a valuable strategy for managing obesity-related hypogonadism. Instead of solely relying on exogenous testosterone, which can suppress endogenous production, GLP-1s provide a pathway to restore natural hormonal balance by tackling the root cause – obesity. This approach can lead to sustained improvements in testosterone levels, body composition, and overall metabolic health, ultimately enhancing the quality of life for obese men.
References
[1] GLP-1 Medications Can Increase Testosterone Levels in Men With ... - https://www.pharmacytimes.com/view/glp-1-medications-can-increase-testosterone-levels-in-men-with-obesity
[2] Obesity drugs may raise testosterone in men - Healio - https://www.healio.com/news/endocrinology/20250715/obesity-drugs-may-raise-testosterone-in-men
[3] GLP-1 Weight Loss Injections and Testosterone in Men - Eden Clinic - https://www.edenclinic.co.uk/post/glp-1-weight-loss-injections-and-testosterone-in-men-can-weight-loss-improve-low-t----and-when-is-trt-still-needed
[4] GLP-1s and Men's Health: A Surprising Connection Worth ... - https://www.legacycommunityhealth.org/newsblog-glp-1s-and-mens-health-a-surprising-connection-worth-understanding/
[5] Does Ozempic Raise or Lower Testosterone? Doctors Explain. - https://www.menshealth.com/health/a61753196/does-ozempic-raise-or-lower-testosterone/
[6] ... of Glucagon-Like Peptide-1 Agonist Therapy (Semaglutide and Tirzepatide) on Metabolic and Hormonal Parameters in Men with Obesity and Insulin Resistance - https://innopublication.com/index.php/jsirs/article/view/156
[7] Semaglutide in Obesity: Unmet Needs in Men - PMC - NIH - https://pmc.ncbi.nlm.nih.gov/articles/PMC9981825/
[8] The effects of semaglutide vs testosterone replacement therapy on ... - https://www.endocrine-abstracts.org/ea/0099/ea0099oc12.5